:max_bytes(150000):strip_icc()/GettyImages-2150746943-29953a04619c4fbe959376f97c6b6a10.jpg?w=1500&resize=1500,1125&ssl=1 "Moderna Stock Soars After First US Bird-Flu Death | Global News Avenue")
Moderna Stock Soars After First US Bird-Flu Death
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2150746943-29953a04619c4fbe959376f97c6b6a10.jpg)
Main points
- Moderna shares rose more than 10% on Tuesday, leading the S&P 500 higher, a day after the first death from bird flu was reported in the United States.
- The biotech company is developing an H5N1 influenza vaccine.
- Despite Tuesday’s gains, Moderna shares are down more than 55% in the past year.
modern (messenger RNAThe company’s shares rose more than 10% on Tuesday, a day after the first death from bird flu was reported in the United States, leading the S&P 500 index higher. biotechnology company yes developing a vaccine for H5N1.
On Monday, the U.S. Centers for Disease Control and Prevention (CDC) said it was “saddened to report that a patient previously hospitalized with severe avian influenza A (H5N1) illness has passed away.” The agency added that this was “not unexpected, as infection with these viruses is known to cause severe illness and death.”
Moderna shares fell sharply last year
The CDC added that as of Monday, “there have been 66 confirmed cases of human infection with H5N1 avian influenza in the United States since 2024 and 67 cases since 2022.”
Moderna shares were up 12% at $47.50 early Tuesday afternoon. Despite the gains, the stock has lost more than half its value over the past year and has performed well Dropped below all-time high In August 2021, at the height of the COVID-19 pandemic, that number was nearly $500.
:max_bytes(150000):strip_icc()/GettyImages-2150746943-29953a04619c4fbe959376f97c6b6a10.jpg?w=1200&resize=1200,0&ssl=1&description=Moderna+Stock+Soars+After+First+US+Bird-Flu+Death+%7C+Global+News+Avenue){kind=link}